GRI Stock Price, Chart, Stats & News
GRI Bio, Inc. (GRI) does not currently pay a dividend.
GRI chart
Fundamentals
Gross margin | -0.01% |
Operating margin | -41.48% |
Pretax margin | -41.41% |
Net margin | -41.41% |
Effective tax rate | – |
ROA | -137.96% |
ROE | -381.74% |
D/E | 0.01x |
Interest coverage ratio | – |
GRI valuation
P/E | – |
P/S | 0.01x |
P/B | 0.19x |
P/CF | -0.11x |
P/FCF | -0.02x |
P/OCF | -0.11x |
PEG | -0.00x |
EV multiple | -0.70x |
About
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.
Similar securities
Based on sector and market capitalization
